



Blastic Plasmacytoid Dendritic Cell Neoplasm Presenting as Erythematous Nodules with Gallbladder Involvement

Sook Hyun Kong, Seok Hyun Han, Ho Seok Suh, Yu Sung Choi

Department of Dermatology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea

Dear Editor:

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, highly aggressive hematopoietic malignancy which is derived from the precursors of plasmacytoid dendritic cells¹. It was recently classified in the 2008 World Health Organization classification². BPDCN can be characterized by a marked predilection for cutaneous involvement in the initial phase, and later develops leukemic dissemination³.

A previously healthy 43-year-old woman presented with 3-week history of nodular eruptions on the face. She had no systemic symptoms. Physical examination did not reveal any abnormalities, except for the skin lesions. Skin examination revealed multiple various-sized erythematous plaques and nodules on the face (Fig. 1). We obtained informed consent for using the photos from the patient. Histopathologic findings showed a diffuse cellular infiltrate in the entire dermis (Fig. 2A). The cells were monomorphic medium sized atypical lymphocytes containing irregular round or indented nuclei with pale cytoplasm (Fig. 2B). Immunohistochemical stains were positive for CD4 (Fig. 2C), CD56 (Fig. 2D), and CD123 (Fig. 2E) and negative for CD3 (Fig. 2F), CD20 (Fig. 2G), myeloperoxidase (Fig. 2H), and terminal deoxynucleotidyl transferase. Microscopic examination of peripheral blood failed to detect neoplastic cells. Abdominal computed tomography

scan disclosed wall thickening of gallbladder (GB). After cholecystectomy, GB involvement of BPDCN was identified by biopsy. Bone marrow biopsy with immunohistochemical stain also revealed anaplastic cells. Thus, BPDCN with skin, GB and bone marrow involvement was diagnosed. The patient received chemotherapy after lymphoblastic lymphoma-type induction protocol. She subsequently underwent allogeneic bone marrow transplantation. There has been no disease progression following 12 months.

BPDCN is a rare hematologic malignancy typically affects older males⁴. In majority of cases, skin is affected at the initial presentation as bruise-like tumefaction or an erythematous nodule^{1,5}. BPDCN is often accompanied by extracutaneous involvement, including bone marrow, lymph node, and peripheral blood but practically any organ can be affected¹. Our patient presented with multiple erythematous nodules on the face, which is a rare pattern in BPDCN to the best of our knowledge^{1,5}. After review of the literature, we believe that the GB involvement described herein has not been documented before.

Pathologic evaluation and immunophenotyping play an important role in the diagnosis of BPDCN, which are char-

Received May 27, 2016, Revised July 20, 2016, Accepted for publication August 7, 2016

Corresponding author: Yu Sung Choi, Department of Dermatology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan 44033, Korea. Tel: 82-52-250-7090, Fax: 82-52-250-7155, E-mail: uuhderma@daum.net

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology



Fig. 1. (A, B) Multiple various-sized erythematous plaques and nodules on the face.




Fig. 2. (A) The tumor is composed of diffuse cellular infiltrate in the entire dermis and subcutis, with an overlying Grenz zone (H&E, $\times 40$). (B) The cells were monomorphic medium sized atypical lymphocytes containing irregular round or indented nuclei with pale cytoplasm (H&E, $\times 400$). Immunohistochemical stains were positive for (C) CD4 ($\times 100$), (D) CD56 ($\times 100$), and (E) CD123 ($\times 100$) and negative for (F) CD3 ($\times 100$), (G) CD20 ($\times 100$), and (H) myeloperoxidase ($\times 100$).

acterized by a diffuse monomorphic infiltrate of medium-sized plasmacytoid cells and the expression of CD4, CD56, and CD123 in the absence of CD3, CD20, or myeloperoxidase^{3,4}.

The clinical course of BPDCN is aggressive with a median survival of 12~14 months^{1,5}. However, there is no standardized therapeutic strategy. High-dose chemotherapy followed by allogeneic stem cell transplantation can provide durable disease control like our patient¹. Several factors, including relatively young age and undergoing stem cell transplantation may contribute to more favorable prog-

nosis in this case.

In conclusion, BPDCN may demonstrate various clinical presentations, which could be quite confusing for the dermatologist to diagnose. Thus histopathologic evaluation of skin biopsy is important to confirm diagnosis. We believe that this case demonstrates a rare cutaneous and extracutaneous presentation of BPDCN and emphasizes the importance of being aware of this rare disease in order to provide effective treatment.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

REFERENCES

1. Kim JH, Park HY, Lee JH, Lee DY, Lee JH, Yang JM. Blastic plasmacytoid dendritic cell neoplasm: analysis of clinicopathological feature and treatment outcome of seven cases. *Ann Dermatol* 2015;27:727-737.
2. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. *Blood* 2005;105:3768-3785.
3. Gera S, Dekmezian MS, Duvic M, Tschen JA, Vega F, Cho-Vega JH. Blastic plasmacytoid dendritic cell neoplasm: evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement. *Am J Dermatopathol* 2014;36:244-251.
4. Nguyen CM, Stuart L, Skupsky H, Lee YS, Tsuchiya A, Cassarino DS. Blastic plasmacytoid dendritic cell neoplasm in the pediatric population: a case series and review of the literature. *Am J Dermatopathol* 2015;37:924-928.
5. Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machel L, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. *Br J Dermatol* 2013;169:579-586.

<https://doi.org/10.5021/ad.2017.29.4.503>



Two Cases of Successful Treatment of Refractory Chronic Inflammatory Skin Disease, Atopic Dermatitis and Psoriasis with Oral Alitretinoin

Jee Hee Son*, Sook Young Park*, Yong Se Cho, Yun Sun Byun, Bo Young Chung, Hee Jin Cho¹, Hye One Kim, Chun Wook Park

Department of Dermatology, Hallym University Kangnam Sacred Heart Hospital, Seoul, ¹Department of Dermatology, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea

Dear Editor:

A 32-year-old man presented with itchy erythematous to brownish skin lesions on the face, neck, trunk and the flexor surface of both extremities starting one year ago (Fig. 1A~C). He has had allergic rhinitis since childhood. With time, his symptoms got worse even with medications including oral steroid and cyclosporin. The initial clinical

suspicion was atopic dermatitis (AD). Microscopic examination showed a chronic inflammatory lesion including focal hyperkeratosis, parakeratosis and irregularly acanthotic epidermis with spongiosis. Mild perivascular inflammatory cell infiltration and dilated vessels were in the dermis (Fig. 1D, E). The final diagnosis was AD. For his refractory AD, oral alitretinoin (30 mg/day) and topical steroid

Received July 11, 2016, Revised August 1, 2016, Accepted for publication August 8, 2016

*These authors contributed equally to this work and should be considered co-first authors.

Corresponding author: Hye One Kim, Department of Dermatology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, 1 Singil-ro, Yeongdeungpo-gu, Seoul 07441, Korea. Tel: 82-2-829-5221, Fax: 82-2-832-3237, E-mail: hyeonkim@gmail.com

Chun Wook Park, Department of Dermatology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, 1 Singil-ro, Yeongdeungpo-gu, Seoul 07441, Korea. Tel: 82-2-829-5221, Fax: 82-2-832-3237, E-mail: dermap@hanmail.net

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology